This strategy has been successful in vitro and in vivo in targeting the Ras/MAPK, EGFR, and IGF-1R kinases in ALK fusion-positive lung cancer, but is not yet applied in the clinic [81,85,110]. This evidence concerns the gene EGFR and lung carcinoma.